Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

obex medical ltd - meglumine amidotrizoate 66%{relative};  ; sodium amidotrizoate 10%{relative};   - oral solution - active: meglumine amidotrizoate 66%{relative}   sodium amidotrizoate 10%{relative}  

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine amidotrizoate 0.18 g/ml; sodium amidotrizoate 0.4 g/ml - solution for injection - 0.18g,0.4g/ml - active: meglumine amidotrizoate 0.18 g/ml sodium amidotrizoate 0.4 g/ml

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine amidotrizoate 65%{relative} - solution for injection - 65% w/v - active: meglumine amidotrizoate 65%{relative}

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

covidien nz ltd - amidotrizoic acid 52%;  ; meglumine 8%; meglumine amidotrizoate; sodium amidotrizoate - solution for injection - active: amidotrizoic acid 52%   meglumine 8% meglumine amidotrizoate sodium amidotrizoate excipient: disodium edetate dihydrate sodium citrate dihydrate sodium hydroxide water for injection

Stati Uniti - inglese - NLM (National Library of Medicine)

fresenius kabi usa, llc - gadoterate meglumine (unii: l0nd3981ag) (gadolinium cation (3+) - unii:azv954tz9n) - gadoterate meglumine injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (mri) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (bbb) and/or abnormal vascularity. history of clinically important hypersensitivity reactions to gadoterate meglumine injection [see warnings and precautions (5.2)] . risk summary gbcas cross the human placenta and result in fetal exposure and gadolinium retention. the human data on the association between gbcas and adverse fetal outcomes are limited and inconclusive (see data) . in animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of gadoterate meglumine during organogenesis at doses up to 16 and 10 times, respectively, the recommended human dose (see data) . because of the potential risks of gadolinium to the fetus, use gadoterate meglumine injection only if imaging is essential during pregnancy and cannot be delayed. the estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20% respectively. data human data contrast enhancement is visualized in the placenta and fetal tissues after maternal gbca administration. cohort studies and case reports on exposure to gbcas during pregnancy have not reported a clear association between gbcas and adverse effects in the exposed neonates. however, a retrospective cohort study, comparing pregnant women who had a gbca mri to pregnant women who did not have an mri, reported a higher occurrence of stillbirths and neonatal deaths in the group receiving gbca mri. limitations of this study include a lack of comparison with non-contrast mri and lack of information about the material indication for mri. overall, these data preclude a reliable evaluation of the potential risk of adverse fetal outcomes with the use of gbcas in pregnancy. animal data gadolinium retention gbcas administered to pregnant non-human primates (0.1 mmol/kg on gestational days 85 and 135) result in measurable gadolinium concentration in the offspring in bone, brain, skin, liver, kidney, and spleen for at least 7 months. gbcas administered to pregnant mice (2 mmol/kg daily on gestational days 16 through 19) result in measurable gadolinium concentrations in the pups in bone, brain, kidney, liver, blood, muscle, and spleen at one month postnatal age. reproductive toxicology gadoterate meglumine was administered in intravenous doses of 0, 2, 4 and 10 mmol/kg/day [3, 7 and 16 times the recommended human dose (rhd) based on body surface area (bsa)] to female rats for 14 days before mating, throughout the mating period and until gestation day (gd) 17. pregnant rabbits were administered gadoterate meglumine in intravenous doses of 0, 1, 3 and 7 mmol/kg/day ( 3, 10 and 23 times the rhd based on bsa) from gd6 to gd19. no effects on embryo-fetal development were observed at doses up to 10 mmol/kg/day in rats and 3 mmol/kg/day in rabbits. maternal toxicity was observed in rats at 10 mmol/kg/day and in rabbits at 7 mmol/kg/day. this maternal toxicity was characterized in rats by a slightly lower litter size and gravid uterus weight compared to the control group, and in rabbits by a reduction in body weight and food consumption. risk summary there are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. however, published lactation data on other gbcas indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk. additionally, there is limited gbca gastrointestinal absorption in the breast-fed infant. gadoterate is present in goat milk (see data) . the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for gadoterate meglumine injection and any potential adverse effects on the breastfed infant from gadoterate meglumine injection or from the underlying maternal condition. data nonclinical data demonstrate that gadoterate is detected in goat milk in amounts less than 0.1% of the dose intravenously administered. furthermore, in rats, absorption of gadoterate via the gastrointestinal tract is poor (1.2% of the administered dose was absorbed and eliminated in urine). the safety and efficacy of gadoterate meglumine at a single dose of 0.1 mmol/kg have been established in pediatric patients from birth (term neonates ≥ 37 weeks gestational age) to 17 years of age based on clinical data in 133 pediatric patients 2 years of age and older, and clinical data in 52 pediatric patients birth to less than 2 years of age that supported extrapolation from adult data [see clinical studies (14)] . adverse reactions in pediatric patients were similar to those reported in adults [see adverse reactions (6.1)] . no dosage adjustment according to age is necessary in pediatric patients [see dosage and administration (2.1), pharmacokinetics (12.3)] . the safety of gadoterate meglumine has not been established in preterm neonates. no cases of nsf associated with gadoterate meglumine or any other gbca have been identified in pediatric patients age 6 years and younger [see warnings and precautions (5.1)] . normal estimated gfr (egfr) is approximately 30 ml/minute/1.73m2 at birth and increases to adult values by 2 years of age. juvenile animal data single and repeat-dose toxicity studies in neonatal and juvenile rats did not reveal findings suggestive of a specific risk for use in pediatric patients including term neonates and infants. in clinical studies of gadoterate meglumine, 900 patients were 65 years of age and over, and 304 patients were 75 years of age and over. no overall differences in safety or efficacy were observed between these subjects and younger subjects. in general, use of gadoterate meglumine injection in elderly patients should be cautious, reflecting the greater frequency of impaired renal function and concomitant disease or other drug therapy. no age-related dosage adjustment is necessary. no gadoterate meglumine injection dosage adjustment is recommended for patients with renal impairment. gadoterate can be removed from the body by hemodialysis [see warnings and precautions (5.1) and clinical pharmacology (12.3) ].

Stati Uniti - inglese - NLM (National Library of Medicine)

fresenius kabi usa, llc - gadoterate meglumine (unii: l0nd3981ag) (gadolinium cation (3+) - unii:azv954tz9n) - gadoterate meglumine injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (mri) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (bbb) and/or abnormal vascularity. history of clinically important hypersensitivity reactions to gadoterate meglumine injection [see warnings and precautions (5.2)] . risk summary gbcas cross the human placenta and result in fetal exposure and gadolinium retention. the human data on the association between gbcas and adverse fetal outcomes are limited and inconclusive (see data) . in animal reproduction studies, there were no adverse developmental effects observed in rats or rabbits with intravenous administration of gadoterate meglumine during organogenesis at doses up to 16 and 10 times, respectively, the recommended human dose (see data) . because of the potential risks of gadolinium to the f

Stati Uniti - inglese - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - gadopentetate dimeglumine (unii: rh248g8v27) (gadopentetate - unii:v7ok6j19hq) - gadopentetate dimeglumine 469.01 mg in 1 ml - magnevist injection is indicated for use with magnetic resonance imaging (mri) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. magnevist injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors. magnevist injection is indicated for use with mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck. magnevist injection is indicated for use in mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body. magnevist is contraindicated in patients with: risk summary gbcas cross the placenta and result in fetal exposure and gadolinium retention. the human data on the association between gbcas and adverse fetal outcomes are limited and inconclusive (see data

Stati Uniti - inglese - NLM (National Library of Medicine)

norbrook laboratories limited - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin meglumine 50 mg in 1 ml - horse: flunixin injection is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle: flunixin injection is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. flunixin injection is also indicated for the control of inflammation in endotoxemia. horse: there are no known contraindications to this drug when used as directed. intra-arterial injection should be avoided. horses inadvertently injected intra-arterially can show adverse reactions. signs can be ataxia, incoordination, hyperventilation, hysteria and muscle weakness. signs are transient and disappear without antidotal medication within a few minutes. do not use in horses showing hypersensitivity to flunixin meglumine. cattle: nsaids inhibit production of prostaglandins which are important in signaling the initiation of partur

Stati Uniti - inglese - NLM (National Library of Medicine)

aspen veterinary resources - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin meglumine 50 mg in 1 ml - horse: vetameg® 50 mg/ml is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle: vetameg® 50 mg/ml is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. vetameg® 50 mg/ml is also indicated for the control of inflammation in endotoxemia. horse: there are no known contra-indications to this drug when used as directed. intra-arterial injection should be avoided. horses inadvertently injected intra-arterially can show adverse reactions. signs can be ataxia, incoordination, hyperventilation, hysteria and muscle weakness. signs are transient and disappear without antidotal medication within a few minutes. do not use in horses showing hypersensitivity to flunixin meglumine. cattle: nsaids inhibit production of prostaglandins which are important in signaling the initiation of partu

Stati Uniti - inglese - NLM (National Library of Medicine)

mwi veterinary supply co - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin meglumine 50 mg in 1 ml - horse: prevail® is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle: prevail® is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. prevail® is also indicated for the control of inflammation in endotoxemia. horse: there are no known contraindications to this drug when used as directed. intra-arterial injection should be avoided. horses inadvertently injected intra-arterially can show adverse reactions. signs can be ataxia, incoordination, hyperventilation, hysteria and muscle weakness. signs are transient and disappear without antidotal medication within a few minutes. do not use in horses showing hypersensitivity to flunixin meglumine. cattle: nsaids inhibit production of prostaglandins which are important in signaling the initiation of parturition. the use of flu